Deinove (ALDEI)

Business description

Deinove is a biotech company that discovers, develops and manufactures compounds of industrial interest stemming from rare bacteria and intended for the health, nutrition and beauty markets.

Stock data

Market cap.€41.4m
Last close€3.51
High / Low (52 weeks)€4.4 / €1.6
Stock market listingEG
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
SectorAlternative Energy

Price performance

Relative *(10.7)36.152.0

* % Relative to local index

Other companies in sector Show

Company news

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2016A 0.8 (6.4) (7.7) (72.6) N/A N/A
2017A 0.2 (8.5) (9.7) (67.7) N/A N/A
2018E N/A N/A N/A N/A N/A N/A
2019E N/A N/A N/A N/A N/A N/A

Last updated on 20/04/2018

Investment summary

A net loss of €7.3m for FY17 was slightly above our forecast figure of €6.9m, due principally to lower revenue than we had assumed. Beyond the financials Deinove made further significant progress during FY17. Deinbiotics was acquired and Deinove secured funding from the ‘Investments for the Future’ programme (€10.4m over five years). FY18 is shaping up to be a pivotal year. Deinove has announced the commercial launch of two products in its cosmetic division, whilst it has also signed partnership agreements with RedX Pharma and Naicons to develop new antibiotics. Most significantly Deinove has announced the proposed acquisition of Morphochem's clinical stage antibiotic compound, MCB3837, and is considering raising additional finance (in part equity), to finance the business. Our forecasts are under review.

Last updated on 27/04/2018

Industry outlook

Environmentalism will underpin growth in green chemistry, and the growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Last updated on 27/04/2018

Key management

Dr Philippe Pouletty, Chairman
Emmanuel Petiot, CEO
Julien Coste, CFO

Company address

22 rue Leon Jouhaux
75010 Paris
01 42 03 27 37
View website